Oncology Medical News about progression of ovarian cancer;loss of programmed cell death 4

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Loss of programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
Molecular Cancer, 09/08/09

Wei N et al. – Loss of Pdcd4 isa common abnormality at molecular level in ovarian cancer and it might be a potential prognostic factor in ovarian cancer patients.

Methods

The expression of Pdcd4 was examined in 30 normal ovarian tissues, 16 borderline and 93 malignant ovarian tissues

Results

A continuous down regulation of Pdcd4 expression in the sequence of normal, borderline and malignant tissues was observed
The expressions of Pdcd4 in both ovarian borderline tissues and carcinomas were significantly lower than the expression in normal ovarian tissues
Patients with lower Pdcd4 expressions were found to have shorter disease-free survival
The expression of Pdcd4 was also assessed by immunohistochemical analysis in 13 ovarian normal tissues and 44 carcinomas
Different subcellular localization of Pdcd4 was observed in normal compared to malignant cells
Predominant nuclear localization of Pdcd4 was found in normal ovarian tissues while ovarian carcinomas showed mainly cytoplasmic localization of Pdcd4

<< Previous
Sliding economy leaves physicians wary about collections

Next >>
The association of plasma androgen levels with breast, ovarian...

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
Annals of Oncology, 11/17/09 Relevance Score: 90%

Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/04/09 Relevance Score: 89%

Toward bold new anti-cancer medicines
EurekAlert, 10/29/09 Relevance Score: 89%

Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer
European Journal of Cancer, 10/20/09 Relevance Score: 89%

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Journal of Clinical Oncology, 10/16/09 Relevance Score: 89%